Dynamic changes during the treatment of pancreatic cancer by Wolff, Robert A et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
3-13-2018 
Dynamic changes during the treatment of pancreatic cancer 
Robert A. Wolff 
Andrea Wang-Gillam 
et al 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Oncotarget14764www.oncotarget.com
www.oncotarget.com                                           Oncotarget, 2018, Vol. 9, (No. 19), pp: 14764-14790
Dynamic changes during the treatment of pancreatic cancer
Robert A. Wolff1,*, Andrea Wang-Gillam2,*, Hector Alvarez8,*, Hervé Tiriac3,*, 
Dannielle Engle3,*, Shurong Hou4,*, Abigail F. Groff6,*, Anthony San Lucas9, Vincent 
Bernard10, Kelvin Allenson11, Jonathan Castillo8, Dong Kim8, Feven Mulu8, Jonathan 
Huang8, Bret Stephens8, Ignacio I. Wistuba9, Matthew Katz11, Gauri Varadhachary1, 
YoungKyu Park3, James Hicks3, Arul Chinnaiyan5, Louis Scampavia4, Timothy 
Spicer4, Chiara Gerhardinger6, Anirban Maitra8, David Tuveson3, John Rinn6,13, 
Gregory Lizee12, Cassian Yee12 and Arnold J. Levine7
1 Department of Gastrointestinal (GI) Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
2 Division of Oncology, Washington University, St. Louis, MO, USA
3 Cold Spring Harbor Laboratory, New York, NY, USA
4 Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA
5 Center for Translational Pathology, University of Michigan Medical Center, Ann Arbor, MI, USA
6 Department of Molecular and Cellular Biology, Harvard University, The Broad Institute, Cambridge, MA, USA
7 Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA
8 Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA
9 Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA
10 Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA
11 Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA
12 Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
13 Current address: University of Colorado Boulder, BioFrontiers Institute, Boulder, CO, USA
* These authors have contributed equally to this paper
Correspondence to: Arnold J. Levine, email: alevine@ias.edu
Keywords: pancreatic cancer; genomic instability; organoids; epithelial-mesenchymal transition
Received: December 20, 2017 Accepted: February 01, 2018 Epub: February 13, 2018 Published: March 13, 2018
Copyright: Wolff et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
This manuscript follows a single patient with pancreatic adenocarcinoma for 
a five year period, detailing the clinical record, pathology, the dynamic evolution 
of molecular and cellular alterations as well as the responses to treatments with 
chemotherapies, targeted therapies and immunotherapies. DNA and RNA samples 
from biopsies and blood identified a dynamic set of changes in allelic imbalances 
and copy number variations in response to therapies. Organoid cultures established 
from biopsies over time were employed for extensive drug testing to determine if this 
approach was feasible for treatments. When an unusual drug response was detected, 
an extensive RNA sequencing analysis was employed to establish novel mechanisms 
of action of this drug. Organoid cell cultures were employed to identify possible 
antigens associated with the tumor and the patient’s T-cells were expanded against 
one of these antigens. Similar and identical T-cell receptor sequences were observed 
in the initial biopsy and the expanded T-cell population. Immunotherapy treatment 
failed to shrink the tumor, which had undergone an epithelial to mesenchymal 
transition prior to therapy. A warm autopsy of the metastatic lung tumor permitted 
an extensive analysis of tumor heterogeneity over five years of treatment and surgery. 
This detailed analysis of the clinical descriptions, imaging, pathology, molecular 
and cellular evolution of the tumors, treatments, and responses to chemotherapy, 
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INTRODUCTION
On December 22, 2011, a patient was diagnosed 
with an inoperable pancreatic adenocarcinoma. After 
Folfirinox therapy, the tumor regressed and became 
operable. It was removed on May 30, 2012. Eighteen 
months later, metastatic lesions appeared in the lungs and 
on the rib cage. It was at this point (Nov.1, 2013) that the 
family decided to assemble a group of scientists who had 
interest in and could carry out extensive surveillance of 
the tumor in the patient and perform experimentation with 
clinical materials collected from blood and biopsies of the 
tumor tissue. The purpose of this was to inform and assist 
the clinicians who were making the decisions about the 
treatment and care of their patient.
The goals of this project were broader than the 
care of a single patient: to follow a number of different 
parameters during the dynamic evolution of a tumor in 
a patient. This was accomplished by obtaining serial 
biopsies and cancer cells and DNA from blood samples 
over the entire time of treatment. A time line was created, 
employing DNA sequencing from blood samples, the 
production of three dimensional, or organoid, tissue 
cultures and two-dimensional cell cultures, from serial 
biopsies (as well as DNA and RNA sequencing of these 
tissues) in order to follow the changes occurring during 
treatments, and tumor response and progression (Figure 1). 
Tumor heterogeneity was explored, detected, and followed 
over time. Possible tumor antigens were identified from 
biopsy samples and organoids. T-cell receptor sequences 
were determined from the peripheral blood and the T-cells 
located in tumor tissue. T-cells from the peripheral blood 
of the patient were expanded with antigen exposure for 
possible therapeutic choices. Attempts at making CAR-T-
cells directed against an antigen observed on the tumor and 
tested in the organoid cultures were explored. Organoid 
cultures were employed to test for drug sensitivities in 
cell culture and in mice and the results were compared 
with expected sensitivities based upon DNA mutational 
profiles observed in the tumors. When some unexpected 
drug sensitivities were identified, an extensive RNA 
sequencing analysis was carried out with tumor tissue 
from mice treated with these drugs and possible pathways 
involved in this treatment were elucidated.
Many of the experimental approaches described 
here were carried out for the first time in cell culture using 
biological materials directly or recently from a patient. 
As such, they represent the forerunner of future paths 
to be taken for the benefit of many patients. In addition, 
these experiments addressed a limitation of past DNA 
sequencing studies with tumor tissue, which explore only 
one time point in the evolution of a tumor. This dynamical 
study follows the changes in DNA sequences and DNA 
sequence heterogeneity with time and treatment (albeit for 
only a single patient). The DNA sequences obtained from 
samples in the blood were compared to those sequence 
changes found in the organoids made from biopsies taken 
at different times. One of the important lessons learned 
from these studies is that the DNA sequences, epigenetic 
states, and properties of cancers evolve with time and 
changing treatment protocols. Precision medicine aspires 
to act upon the biological information about a tumor, to 
craft an informed and intelligent treatment response. We 
will have to learn how to obtain information about the 
tumor rapidly, so as to intervene before the tumor changes 
its basic information. This report reflects an attempt to do 
just that.
The authors of this unusual research venture formed 
a team to exchange biological samples, information, new 
experimental protocols, and novel ideas and directions. 
They often held joint meetings and phone conferences 
to stay focused, organized, and informed about new 
observations. They all sacrificed time and effort from other 
research projects and activities, because they all came to 
appreciate the rewards of helping an individual patient, 
perhaps more directly than previous research avenues in a 
laboratory had permitted.
 CLINICAL BACKGROUND
A previously healthy, 50-year-old Jewish man 
presented with intermittent back pain and epigastric 
discomfort beginning in 8/2011. Computed tomography 
of the abdomen in December 2011 revealed a 7.3 cm x 2.9 
cm mass in the body of the pancreas, encasing the splenic 
artery and extending along the celiac axis. The mass was 
also abutting the proximal common hepatic artery and 
superior mesentery artery. Endoscopic ultrasound with 
fine needle aspirate of the pancreatic mass was performed 
with cytology positive for adenocarcinoma. The patient’s 
family medical history was notable for a sister with 
breast cancer in her 60s and a father with prostate cancer. 
Carbohydrate antigen 19-9 was within normal limits and 
germline mutational testing was negative for a deleterious 
BRCA 1 or 2 mutation. The majority of the patient’s 
clinical care was coordinated between MD Anderson in 
Houston and Siteman Cancer Center in St. Louis.
In light of the tumor’s extensive vascular 
involvement, the patient was started on 5-FU, leucovorin, 
oxaliplatin and irinotecan, FOLFIRINOX). After a total of 
4 cycles of chemotherapy, there was radiographic evidence 
of response. The patient received 1 more dose and he then 
targeted therapies, and immunotherapies, as well as attempts at the development of 
personalized medical treatments for a single patient should provide a valuable guide 
to future directions in cancer treatment.
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proceeded with chemoradiation. The patient received 
gemcitabine-based chemoradiation to a total radiation 
dose of 50.4 Gy with one dose of bevacizumab at the 
initiation of radiotherapy and 2 weekly doses of cetuximab 
as radiation completed. The patient tolerated the treatment 
well, and follow-up CT imaging revealed significant tumor 
regression. Tumor shrinkage was seen on repeat imaging.
The patient was referred to the Medical College of 
Wisconsin and underwent an R0 distal pancreatectomy 
and splenectomy; the common hepatic artery was spared. 
Pathology confirmed a stage IIA (T3N0M0) pancreatic 
cancer with significant treatment-effects response. The 
patient’s post-operative course was uneventful, followed 
by two months of adjuvant therapy comprised of 
gemcitabine, capecitabine and nab-paclitaxel.
Close radiographic and clinical surveillance for 
relapse revealed no evidence of disease until November 
2013, 18 months postop. At that time, small lung lesions 
and a rib lesion were noted. The patient and his family 
assembled a team of clinicians and scientists that could 
provide further expert clinical guidance and devise 
scientifically sound novel therapeutics. Thorascopic 
wedge resection of a left lung lesion confirmed metastatic 
disease with residual tissue used to create organoids and 
patient derived murine xenografts. The patient resumed 
FOLFIRINOX treatment along with denosumab. The 
patient had a minor radiographic response to therapy and 
after 4 months of therapy, he was placed on maintenance 
infusional 5FU with disease remaining stable through 
November 2014. During this interval, single cell analysis 
from tumor derived organoids demonstrated amplification 
of HER2 and the patient was tried on capecitabine plus 
trastuzumab. Tumor progression was documented after a 
6-week course of therapy.
In February 2015, shortly after a brief chemotherapy 
holiday, the patient presented with shortness of breath 
caused by a new onset of right pleural effusion. Malignant 
cells were seen in the pleural fluid. FOLFIRINIX was 
resumed with the addition of bevacizumab. Bevacizumab 
was discontinued after asymptomatic pulmonary embolism 
was noted. Anticoagulant therapy was initiated and 
FOLFIRINOX was continued. By June 2015, the patient 
had disease progression in the lung, and he was started 
on gemcitabine and nab-paclitaxel with paricalcitol. 
The patient had a minor response to gemcitabine, nab-
paclitaxel, and paracaltriol for 2 months with progression 
after 2 more months of treatment.
In October 2015, the patient enrolled in a clinical 
trial at MD Anderson, which administered autologous 
T-cells enriched for reactivity to VMMR-1. A non-mutated 
antigen was found, based on organoid peptide analysis. 
Based on the study protocol, he received Cytoxan, 
followed by T cell infusion, then subcutaneous IL-2 
injections and pembrolizumab. The patient experienced 
significant weight loss and fatigue during the therapy. 
He required frequent therapeutic thoracenteses for 
Figure 1: Patient clinical course throughout a four year period. Size of lung and pleural metastatic lesions were used to 
determine response to therapies (left axis). CA-19-9 levels are plotted, although remain mostly within normal range (right axis).
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palliation of dyspnea. A repeat CT scan of the chest in 
11/2015 showed rapid disease progression, manifested 
as an interval increase in lung lesions and pleural-
based metastatic disease. Surprisingly, the biopsy of a 
pleural-based nodule revealed a poorly differentiated 
neuroendocrine tumor.
In light of the rapid disease progression, a 
combination of 5-FU, gemcitabine, docetaxel and cisplatin 
was initiated on 12/14/2015. The patient’s respiratory 
status deteriorated and he was intubated two days later. 
Concern of an acute inflammatory response was raised, 
and high dose steroid therapy was instituted. A similar 
chemotherapy regimen was administered two weeks later, 
and the repeat CT revealed stable pleural caking and 
lung metastatic lesions. Although tumor stabilization was 
achieved with resumption of cytotoxic chemotherapy, he 
remained with restrictive lung disease and he opted for 
a tracheostomy for persistent hypoxemia and hypercarbic 
respiratory failure requiring mechanical ventilation. He 
had clear mentation with intact organ functions.
On January 6, 2016, the patient was transferred 
to Barnes Jewish Hospital in St. Louis. He was treated 
with carboplatin and etoposide for poorly differentiated 
neuroendocrine tumor histology. Therapy was delivered in 
an intensive care unit, and he subsequently transferred to 
an immediate care floor for ventilator care given his stable 
clinical condition. A repeat FNA of the pleural lesion 
was performed and cytology revealed mixed histology 
Figure 3: Treatment monitoring for a metastatic PDAC patient with 15 liquid biopsies. The graph illustrates the rise and fall 
of molecular and clinical indicators in the context of cancer treatments.
Figure 2: H&E staining of lung metastatic biopsy taken at the beginning (left) and end (middle and right) of liquid 
biopsy follow up. Histological analysis demonstrates a phenotypic change from adenocarcinoma to small cell-like tumor. Rapid autopsy 
samples show phenotypically distinct lesions comprising neuroendocrine and ductal-like histologies.
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malignancy with predominant neuroendocrine tumor in 
addition to features of adenocarcinoma. Meanwhile, the 
patient had suffered a ventilator-related tracheostomy 
infection, pneumonia, fungal infection and bilateral lower 
extremities DVT. His clinical condition declined over the 
hospital stay despite normal neurocognitive function and 
adequate cardiac, renal, and hepatic function. The patient 
requested ventilator support be withdrawn and he expired 
shortly thereafter, 50 months from his initial diagnosis of 
pancreatic cancer.
Evolving genomic landscapes of a metastatic 
PDAC patient through liquid biopsies and multi-
region sequencing
Fifteen months after the wedge resection, the patient 
began to be monitored by the liquid biopsy program at 
Figure 4: Heatmap of COSMIC mutations detected across tissue samples. Only those mutations present in at least two distinct 
lesions were considered based on a consensus approach. TB1 and TB2 corresponds to a wedge and core biopsy acquired on 12/2013 and 
12/2015 respectively. TB4-TB13 are tissues acquired from rapid autopsy on 02/2016.
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MD Anderson in the Maitra lab. A total of eighteen 
liquid biopsies (15 peripheral blood and 3 malignant 
pleural effusions) were performed throughout disease 
progression and therapeutic intervention, which include 
chemotherapies, targeted therapies, and immunotherapies. 
Subsequently, the patient underwent a second lung biopsy 
(a core needle biopsy). The core needle biopsy (CNB) 
was histologically determined to be a metastatic neoplasm 
with high-grade neuroendocrine features (Figure 2). At the 
time of death, rapid autopsy was performed on the patient, 
at which point seven spatially distinct lung metastatic 
lesions acquired for molecular analysis. Disease response 
was primarily determined by CT imaging as the standard 
clinical biomarker, CA-19-9, remained within normal 
ranges throughout disease course. The tissue and liquid 
biopsies were utilized as an ancillary decision support for 
this patient, as follows:
KRAS and TP53 mutations as surrogates of 
patient tumor burden
Next-generation sequencing (NGS) analysis of 
both the patient’s initial metastatic tumor (histologically 
consistent with an adenocarcinoma) and second lung 
metastasis (histologically consistent as a high grade 
neuroendocrine carcinoma) samples harbored oncogenic 
KRAS G12D and TP53 R175H mutations, along with 
several truncal genomic imbalances, with concordant 
changes in gene expression (ERBB2, FOXO1, KLK2, 
NRAS, DAXX, HMGA1 and NOTCH2 amplifications and 
a FHIT deletion) suggesting that the metastatic small cell 
carcinoma was not a new primary tumor, but rather an 
evolution of the original metastatic PDAC.
Since KRAS represents a reliable tumor burden 
surrogate for PDAC (seen in close to 95% of PDAC) 
Figure 5: Detection of allelic imbalance events by hapLOHseq across sequenced tissue samples. Representative events are 
highlighted to depict distinct patterns of chromosomal aberrations across tissue sites.
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it was decided to perform ultrasensitive droplet digital 
PCR (ddPCR) in the complete series of 15 blood based 
liquid biopsies [1]. Mutation allele frequencies (MAFs) 
of the driver KRAS in both the exosomes-derived DNA 
(exoDNA) and circulating cell-free DNA (cfDNA) were 
plotted against clinical covariates (Figure 3). The MAFs 
for both compartments trended with patient tumor burden, 
including size of the pulmonary metastases (sum of the 
largest dimension, “SLD” according to RECIST 1.1 
criteria), suggesting that these mutations are representative 
of tumor burden. Notably, the tumor burden (as determined 
by exoDNA and cfDNA mutant KRAS allele fraction) rose 
from non-detectable to detectable levels when therapy was 
changed from FOLFIRINOX to Gemcitabine/Abraxane, 
and thereafter, sharply spiked after the patient received 
adoptive T-cell therapy, finally regressing once the 
patient resumed cytotoxic chemotherapy comprised of a 
“cocktail” of agents, including cisplatin, carboplatin and 
etoposide (amongst others).
Landscapes of genomic heterogeneity in 
metastatic tumor tissue
At the time of death, rapid autopsy retrieved seven 
warm biopsies of the lung tissue metastasis, representing 
distinct spatial lesions, with the goal of determining 
patterns of heterogeneity. Tumor regions were separated 
by a margin of at least 0.5cm in order to be considered 
a spatially distinct lesion, and were compared to the two 
prior biopsy samples (Figure 4 TB1 and TB2). Significant 
heterogeneity among putative subclonal driver mutations 
began to accumulate over time, and these were partially 
shared across tissue samples. These included mutations 
in STK11 and NOTCH2, which have been previously 
described to have a role in PDAC carcinogenesis, and a 
secondary mutation in TP53, which may have been related 
to selective pressures induced by this patient’s prolonged 
therapeutic history [2, 3].
Figure 6: Heatmap of detected copy number variations detected across tissue samples. Only CNVs previously associated 




Identification of chromosomal allelic imbalance (AI) 
may indicate ongoing chromosomal instability, and can be 
inferred through whole exome sequencing. As a result of 
chromosomal deletions or duplications, AI profiles provide 
insights into patterns of tumor progression, with potential 
correlates to prognosis and therapeutic actionability. 
In order to overcome the challenges of detecting subtle 
chromosomal AI, due to diluted tumor fractions such as 
those seen through liquid biopsies, the MD Anderson 
team applied a methodology known as hapLOHseq [4]. 
In doing so, they sought to identify unique temporal and 
spatial patterns of AI in distinct biopsies taken throughout 
a more than two-year period. As depicted in Figure 5, 
they observed pre-existing AI events on chromosomes 2 
and 11, present since the wedge biopsy (genomic regions 
shaded in yellow) taken from 2013, but spatially diverse 
in subsequent multiregion whole exome sequencing two 
years later. Further events on chromosomes 10 and 15 
(shaded in blue) demonstrate the emergence of aberrations 
that may be directly related to the evolution of this tumor 
genome.
Copy number aberrations
Although progression of PDAC has been suggested 
to occur over a period of nearly two decades, affording 
a window of promise for early detection biomarkers, 
recent studies have suggested that rather than a step-wise 
molecular sequence of aberrations, PDAC tumorigenesis 
may follow a model similar to what is termed punctuated 
equilibrium [5]. Specifically, it is possible that most 
mutations accrue in an extended phase under pre-
neoplastic tumor development, but a single transformative 
event, which may be influenced by genomic instability 
from copy number variations (CNVs), induces a 
transformative effect facilitating overt metastasis. This 
underlies the functional importance of CNVs in the PDAC 
tumorigenesis and potential mechanisms of therapeutic 
resistance. Thus, patterns of copy number evolution 
were studied over time to determine if these events 
were related to disease status. As depicted in Figure 6, 
significant heterogeneity of copy number changes is 
Figure 7: Mutation patterns were defined for each tumor sample using inferred exome sequencing mutations. These 
signatures were then decomposed into putative combinations of known mutation signatures (using COSMIC mutation signatures), where 
signatures 3, 4 and 6 were highly prevalent across the tissue samples and have previously been associated with deficiencies in DNA-double-
strand break repair, exposure to tobacco carcinogens and defective DNA mismatch repair respectively.
Figure 8: A. The biopsy is a CNB with a lot of crush artifact, but PARP IHC seems strongly positive as compared with a known positive 
control of a human SCLC. B. (Thermo cat# RB-1516-P, rabbit polyclonal, 1:100). Panel C. represents a negative control without primary 
antibody.
Oncotarget14772www.oncotarget.com
present among previously identified PDAC related core 
signaling pathways [1, 6-8]. CNVs present in the initial 
wedge biopsy appear to be rare among PDAC related core 
pathways, although it is important to note the identified 
amplification in ERBB2, which led to targeted therapy 
selection using Trastuzumab, to which the patient did not 
respond. Subsequent tissue profiling through a core biopsy 
showed that the patient’s tumor harbored amplification and 
overexpression in the EGFR gene, potentially providing a 
resistance mechanism to this therapy.
With tumor progression, clonal aberrations appeared 
among KRAS and CDKN2A, as well as genes related to 
SWI/SNF mediated chromatin remodeling. Of particular 
interest, is the emergence of MYC amplifications detected 
in all rapid autopsy lesions. Although this was not found 
in the core biopsy two months prior, it is possible that 
this CNV was missed due to limited sampling of spatial 
heterogeneity from a single core biopsy. A greater 
degree of heterogeneity appears to be present among 
axon guidance and other oncogenic pathways, which 
include amplifications and deletions of the same gene 
across spatially distinct tissue samples (ROBO1 and 
GATA6). Spatial heterogeneity among tissue samples also 
exists in genes such as PIK3CA. Of note is a significant 
amplification of DNA damage repair genes (BRCA1 
and BRCA2), which may be related to compensatory 
mechanisms of DNA repair in an unstable genomic 
background. It is important to note, however, that 
distinguishing evolutionary copy number events from 
stochastic aneuploidy may be challenging, underlining the 
importance of observing such events in a relevant context.
Inferring mutational signatures in PDAC
Elucidation of mutational signatures across tissue 
samples revealed the presence of previously described 
“BRCAness” mutational patterns, which are representative 
of unstable genomes (Figure 7) (1). Signatures that likely 
are a consequence of DNA repair deficiency include 
COSMIC mutation signature 3, which is associated 
with deficiencies in DNA-double-strand break repair, 
and signature 6, which is associated with defective 
DNA mismatch repair. This BRCAness signature is 
putatively associated with DNA Damage Repair (DDR) 
aberrations in cancers, for which DNA damaging drugs 
may prove effective, such as platinum compounds like 
cisplatin and oxaliplatin, or PARP inhibitors. Tumor 
tissue profiles experienced an increase in load of genomic 
aberrations (specifically, structural variations) over 
time, suggestiing that the patient’s tumor was, in fact, 
DDR deficient. Correlated to this hypothesis, the patient 
consistently responded to therapies involving platinum 
based chemotherapies such as FOLFIRINOX and readily 
progressed when switched to Gemcitabine based regimens.
PARP overexpression underscores a state of 
ongoing DNA repair defect
To further elucidate whether alternative DNA 
repair mechanisms were active in the tumor, RNA 
sequencing analysis was performed on the last core 
biopsy, demonstrating high expression of PARP (128.62 
TPM) in the tumor (6 fold more expressed than normal 
pancreas in TCGA). Furthermore, immunohistochemical 
analysis confirmed PARP overexpression within the 
high-grade neuroendocrine tumor compartment (Figure 
8). Overexpression of this protein is seen in a variety 
of cancers, and can be associated with poorer overall 
survival. Moreover, PARP overexpression, in the context 
of cancer harboring mutations in DDR pathway, leads 
to the option of using PARP inhibitors as a potential 
therapeutic strategy. Further evidence supporting this 
hypothesis comes from the noticeable, albeit transient, 
reduction in tumor burden, upon administration of a 
cisplatin-containing regimen (Figure 8).
The MD Anderson studies show the potential 
clinical utility of liquid biopsies for the monitoring and 
clinical guidance of an advanced PDAC patient. They 
Figure 9: Isolation of hM1 cultures from a lung metastasis. hM1 cancer cells were isolated and grown as a three-dimensional 
organoid A., and adapted to monolayer culture B. Cancer associated fibroblast (hM1-CAF) were isolated as a monolayer culture C. (Scale 
bars = 200 µm).
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demonstrate that circulating MAFs of driver mutations 
can be representative of tumor burden and that these 
values correlate with clinical response. These molecular 
measures are shown to be especially useful in the case of 
the subject patient, where CA19-9 (a traditional tumor 
burden measure) was within normal ranges during the 
majority of his care. The studies demonstrate the temporal 
and spatial genomic landscapes of this patient’s tumor, 
identifying arising putative driver aberrations in the form 
of single nucleotide variants, copy number changes, and 
gross chromosomal imbalances, depicting the inherent 
heterogeneity that is present within PDAC. Based on these 
molecular signatures, it is subsequently possible to select 
for candidate therapies that may be most beneficial to the 
patient.
Organoids, cell lines, sequencing and therapeutics
Following the surgical resection of the lung 
metastasis and the confirmation of pancreatic 
adenocarcinoma by pathologists at MD Anderson Cancer 
Center, the Tuveson lab at Cold Spring Harbor Laboratory 
received four different biopsy specimens, each consisting 
of multiple tissue fragments. Each sample contained 
differing contributions of tumor and normal cells and 
was processed independently as a different sub-line of 
human metastatic organoid 1 (hM1) (labeled A - D). These 
samples were used to prepare organoids, and a small 
portion was formalin fixed and paraffin embedded for 
independent validation of neoplastic content and cellular 
composition. Within 48 hours, small organoids were 
Figure 10: Histologic analysis of hM1 organoids. Representative images of the different morphologies by H&E A., C., F. and 
Alcian Blue/Mucin-production stain B., D., E. (Scale Bar = 50µm).
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detectable in each individual isolate. Upon passaging, the 
Cold Spring Harbor Laboratory team began evaluating 
modifications of the basal media using parameters that 
were being established for human normal and tumor 
pancreatic organoid lines [9]. This optimization allowed 
exponential expansion of the hM1 organoids (Figure 9).
Figure 11: hM1 DNA copy number analysis heatmap. Single cells derived from organoids at passage 6 and 8, and from monolayer 
culture at passage 2 were analyzed for DNA copy number (CN) gain or loss. The predominant clonal features appear in all three cultures 
(*), while normal-like cells are only present in early passages of the organoid cultures (**).
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In parallel to organoid isolation, a cancer-associated 
fibroblast line (hM1-CAF) and an organoid-derived 2D 
cancer cell line (hM1-2D) were established. Generation 
of a monolayer cell line directly from the patient specimen 
failed. In addition, patient derived xenografts were 
established from four fragments from which one tumor 
engrafted and was passageable following six months 
of growth in vivo. The morphology of the organoids 
consisted of both single- and multi-layer spheroids (Figure 
10), similar to previously generated human organoid lines. 
Although the patient did not exhibit serological elevation 
of the pancreatic cancer biomarker, CA19-9, it was 
highly expressed in the organoids, using flow cytometry 
and immunoblot (data not shown). The findings suggest 
that this biomarker is expressed by the tumor cells, but 
not shed in large amounts, as observed in some PDAC 
patients.
To better assess the heterogeneity of the hM1 
Figure 12: Copy number analysis of hM1. A. Copy number analysis of a representative single cell clone of hM1. B. Copy number 
of primary metastatic tissue after laser dissection (~40% neoplastic cellularity).
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Figure 13: High throughput therapeutic screen of hM1 cells identifies high efficacy targeted inhibitors. Growth inhibition 
effect in hM1 cancer cell line A. and in cancer associated fibroblasts B. in response to 3200 approved agents. Dose response curves for 
cytotoxic chemotherapeutics C. and D. and selected targeted inhibitors in therapeutic screen E. and F.
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organoid culture and to discern potential therapeutic 
avenues, copy number analysis (CNA) was at the single 
cell level. To account for potential genetic selection in 
the cultures, analysis was performed on hM1A organoids 
at two different passages, as well as cells derived from 
a monolayer culture of hM1A that were established 
using early passage organoids. This experiment tested 
48 single cells derived from two different passages of 
the organoid culture and compared them to 48 cells 
grown as a monolayer. DAPI-stained DNA from single 
nuclei was amplified and analyzed using next generation 
sequencing to determine copy number variation (Figures 
11 and 12A). This analysis revealed that hM1A organoid 
cultures are oligoclonal and display distinct gene copy 
number gains and losses, which are recapitulated both in 
2D and 3D cultures. The single cell CNA of organoids 
mirrors the genetic analysis performed at the University of 
Michigan using frozen metastatic tissue and also reveals 
distinct and numerous copy number alterations that are not 
apparent in bulk tumor analysis. (Figure 12A and 12B).
The method provides a highly detailed genomic landscape 
that illustrates which molecular mechanisms are altered 
in the tumor. For instance, the complete loss of RB and 
the amplification of Cyclin E1 would lead to a loss of the 
G1/S cell cycle checkpoint. In addition, the Cold Spring 
Harbor Laboratory Team study predicts a strong activation 
of the Mitogen-Activated Protein Kinase pathways, given 
that KRAS, EGFR, and HER2 are amplified (4.95, 3.79, 
and 3.05 copies per cell on average, respectively).
The ultimate goal of the Cold Spring Harbor Lab 
Figure 14: Thoracentesis-derived cell lines hM1P1 and hM1P2 contain KRAS-G12D genetic lesion. Lung metastasis-
derived hM1A-2D A. is show next to thoracentesis-derived hM1P1-2D and hM1P2-2D cell lines C. & D. All three cell lines contain the 
KRAS-G12D mutation (targeted sequencing of KRAS shown in inset). When received from the clinic, the pleural effusion contained a 
majority of mesothelial cells B. (Scale bar = 200 µm).
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team was to identify and exploit potential therapeutic 
strategies against hM1 organoids. The single cell CNA 
highlighted CDK and the ErbB pathway as potential 
therapeutic targets. The CSHL group also initiated 
collaboration with the Scripps Research Institute High 
Throughput Screening (HTS) core to empirically discover 
additional therapeutic approaches. The goal of the 
collaboration was to perform unbiased screening of FDA- 
approved compounds that could be rapidly applied in the 
clinic. The Scripps Institute compiled a library of ~3200 
compounds using approved agents in the USA, Europe, 
and Japan, and employed a pipeline amenable to HTS 
in monolayer cultures. Cold Spring Harbor Laboratory 
designed a screening approach to maximize the discovery 
of compounds selectively cytotoxic to hM1 cancer cells 
and fibroblasts by including both the hM1 monolayer 
cell line and the hM1-CAF (cancer-associated fibroblast) 
line (SV40 immortalized). The cells were adapted to 
a 1536-well plate format and the primary screening 
against the compound library given at a single dose was 
performed. 23 highly-cytotoxic agents achieved more than 
80% inhibition of hM1-2D growth in the screen (Table 
1). Five additional drugs were specifically evaluated 
because they would be part of standard of care or could 
potentially target hM1 genetic vulnerabilities such as 
the amplification of the ERBB receptor tyrosine kinase 
family. The team selected compounds for secondary 
screening and full dose response assay (Figure 13), and 
identified a small subset of hM1-selective cytotoxic 
and targeted agents. The MEK inhibitor Trametinib 
was one of the most potent and selective agents, with 
an observed EC50 of 19 nM. As previously suspected, 
with amplification of EGFR and HER2 in hM1 cells, the 
pan-ErbB inhibitors, Afatinib, and Neratinib, were very 
effective against hM1 cancer cells. The identification of 
molecular targets in the ErbB and MAPK cascade is not 
surprising in a KRAS mutant cancer cell [10]. Disulfiram 
was also identified as an unexpected compound with 
high activity against hM1 with an observed EC50 of 316 
nM. Disulfiram is currently prescribed in the USA as a 
treatment for chronic alcoholism due to its inhibition of 
acetaldehyde dehydrogenase [11]. Surprisingly, Disulfiram 
was also identified as a top hit in HTS assays against 
prostate and breast cancer cell lines [12, 13], and many 
anti-cancer activities in various cancer types have been 
described, such as proteasome inhibition [14, 15, 16, 17]. 
Additionally, the proteasome inhibitor Bortezomib is also 
a potent cytotoxic for hM1- 2D and hM1-CAF, and does 
not provide selective effect on the cancer cells.
Throughout the clinical care of the patient, 
repeated biopsies allowed generation of additional 
organoid and cell line cultures. Two independent 
thoracenteses were performed at the Washington 
University Hospital in St. Louis and at MD Anderson in 
Houston (early 2015). The Cold Spring Harbor Laboratory 
team received a pleural effusion sample from each medical 
institution and generated two hM1P (pleural) organoid 
and monolayer cell lines (Figure 14). They observed that 
Trametinib, Neratinib, and Disulfiram maintained their 
activity in the newly generated hM1P cell lines, whereas 
the chemotherapeutic gemcitabine was now less active, 
hinting at an acquired resistance to ongoing therapy 




To validate targeted therapeutic strategies, the 
CSHL team generated hM1A mouse xenografts. The 
genetic alterations present in hM1 organoids, such as the 
KRAS-G12D and TP53-R175H mutations, render hM1A 
cells very aggressive when transplanted orthotopically 
into the pancreas of immunocompromised mice (Figure 
16). Large desmoplastic tumors grew in the pancreas of 
the mice, and a high frequency of lung metastasis with 
remarkable recapitulation of the histopathology of the 
primary metastatic tissue was observed (Figure 16). The 
acquired resistance to chemotherapy seen in hM1P cells 
highlighted the need for targeted therapeutic options for 
the patient, therefore, a subset of regimens in the hM1A 
orthotopic xenografts was tested. The regimens tested 
included Disulfiram, Trametinib, and the combination of 
both agents (Figure 17). Whereas single agent Disulfiram 
did not induce a tumor regression, the MEK inhibitor 
Trametinib did lead to tumor regression in 2/6 mice. The 
combination of both agents led to the largest effect on 
tumor burden, with more substantial tumor regressions 
observed in 4/6 mice, indicating that potentially these 
compounds could have been beneficial to the patient. Yet, 
some mice did not respond to the combination (2 out of 
6), highlighting the possible impact of oligoclonality on 
therapeutic response.
After the patient was hospitalized with highly 
progressive disease in early 2016, a core needle biopsy 
obtained from the Washington University Hospital in St 
Louis was used to generate a novel organoid line hM1E. 
Figure 16: hM1 orthotopically grafted organoid (OGO) recapitulate human tumor histopathology. Two representative 
H&E images of the patient’s lung metastatic tissue A. compared to large desmoplastic and mucinous mouse pancreatic tumors B., and 
mouse lung metastases C. (Scale bar = 100 µm).
Oncotarget14780www.oncotarget.com
Shortly thereafter, the patient passed away with a large 
tumor burden. Tissue was received from the rapid autopsy, 
from which was generated one final organoid line (hM1F). 
All of these cancer models maintained the original 
KRAS-G12D mutation (data not shown). To understand 
the drug resistance and sensitivity changes over time in 
serial organoid cultures, the activity of standard of care 
chemotherapeutic compounds and targeted agents in 
the hM1 organoid series was determined (Figure 18). 
Although the chemotherapeutic cytotoxic agents display 
activity in the early organoid hM1A, they lose their 
potency in the late hM1E biopsy and the autopsy-derived 
hM1F organoids. Furthermore, targeted agents such as 
Bortezomib and Afatinib are also less effective in the 
late-disease derived organoids. Some compounds do not 
display a change in activity, such as Selumetinib and 
Olaparib. The response observed in the organoids mimics 
the resistance observed in the patient with advanced 
disease, indicating that the organoid system may represent 
a robust system for precision medicine. Intriguingly, the 
testing results using the mTOR inhibitor Everolimus 
demonstrate increased sensitivity in hM1E and hM1F. 
This is in line with the pathological findings that the 
pancreatic ductal adenocarcinoma phenotype switched 
into a poorly differentiated small cell-like, neuroendocrine 
state. Pancreatic neuroendocrine carcinomas are known to 
be responsive to mTOR inhibition [18, 19], suggesting 
that MTOR inhibition might have been a viable clinical 
strategy.
RNA and drug profiles
The Rinn lab at Harvard performed a molecular 
profile to understand how the tumor, hM1, responded to the 
top drugs screened by the Tuveson group at Cold Spring 
Harbor Laboratory. Specifically, the Rinn lab focused on 
Trametinib and Disulfiram, the former being administered 
to the patient, and the latter showing important synergistic 
effects in tumor reducing capabilities in the screen. The 
goal was to profile the entire transcriptome for gene-
regulatory changes of mRNA, and the possible roles 
of long noncoding RNAs as an unexplored area. hM1 
PDX models treated with Trametinib and Disulfiram 
(at a dosage of 3mg/kg, and 80mg/kg respectively) 
were analyzed in parallel with a vehicle control. The 
Figure 17: hM1 OGO mouse therapeutic study of selected compounds. Response to therapy quantified by ultrasound of the 
tumor before and after treatment in Immuno-compromised mice (NSG) orthotopically grafted with hM1 organoid tumor pieces.
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organoid treatment was performed by the Tuveson lab in 
quadruplicate (triplicate for Trametinib). After 7 days of 
exposure, tumors were harvested and snap frozen. The 
Rinn lab then isolated total RNA and prepared sequencing 
libraries (TruSeq, Illumina) for massively parallel RNA 
sequencing. The samples were sequenced on a HiSeq with 
an average depth of 39.8 million reads per replicate (437 
million reads total; 50bp reads, paired-end sequencing). 
Finally, differential expression analyses (methods) were 
performed to determine genes that were significantly up 
or down regulated in Trametinib and Disulfiram relative 
to vehicle control.
The largest impact was observed on transcriptional 
regulation in the Disulphiram-treated samples, with a 
total of 396 mRNA genes differentially regulated (145 up 
and 251 down) in treated vs. vehicle control. In contrast 
to Disulfiram, in the Trametinib-treated samples, only 93 
mRNA genes were misregulated (48 up and 45 down) 
Figure 18: Therapeutic testing of hM1 organoid cultures. Dose response assay with hM1A (blue lines), hM1E (red lines), and 
hM1F (green lines) organoids, for chemotherapeutic agents and targeted agents.
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Figure 19: Transcriptional analysis of top drug targets. A. Significantly dysregulated mRNA genes in either Disulfiram-vehicle 
or Trametinib-vehicle. Log2 fold change of each replicate is shown relative to vehicle replicate 0. B. Significantly dysregulated lincRNA 
genes. Log2 fold change of each replicate is shown relative to vehicle replicate 0. C. Reactome gene ontology enrichment (BH adjusted 
p-value < 0.01) for genes significantly dysregulated in disulfiram samples. D. Log2 fold change of PI3K pathway genes in each sample 
relative to vehicle replicate 0. E. Expression in FPKMs of TNS4. F. Expression in FPKMs of lincRNA RP5-1028k7.2. G. Raw RNAseq 
read pileup across the RP5-1028k7.2 locus, with gene structure shown above.
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relative to the vehicle control (Figure 19A). Interestingly, 
it was possible to detect differential transcription of 24 
lncRNAs (21 differentially expressed in Disulfiram-treated 
samples and 3 in Trametinib-treated samples, Figure 
19B). The Rinn lab next performed gene ontology (GO) 
enrichment analyses to determine if there were trends in 
specific gene pathways or processes that were commonly 
mis-regulated. They were unable to find coherent gene 
expression changes in the Trametinib experiments (data 
not shown) but found a clear signature of PI3 Kinase 
pathway regulation in the Disulfiram-treated samples 
(Figure 19C). They further investigated the specific genes 
defining this signature and found that the vast majority 
were down-regulated (Figure 19D). Together, these 
analyses suggest that Disulfiram may strongly down-
regulate PI3K signaling in tumors.
The Rinn lab next looked for long noncoding RNA 
(lncRNA) regulation with a particular focus on lncRNAs 
that are mis-regulated in Disulfiram-treated samples. They 
also looked for lncRNAs neighboring mRNA genes that 
showed coherent down-regulation, potentially implicating 
the lincRNA in cis regulation of the mRNA at that locus. 
Such a gene expression pattern would provide a new 
avenue of therapeutic intervention—targeting the lncRNA 
Figure 20: The number of DNA sequence reads of T-cell receptors from the total leukapheresis (sample 1) and from 
the metastatic lung tumor (TP_2047(y), obtained Nov. 2013) (sample 2). The high clonal counts of T-cell receptor sequences from 
the leukapheresis (in blue) and from the tumor (in orange) are presented and the sequences that are expanded clonally in both samples are 
in the upper right corner of the graph.
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to down-regulate the neighboring mRNA. Indeed, they 
found the lncRNA RP5-1028K7.2 to be significantly 
down-regulated in Disulfiram-treated samples with a 
concomitant down-regulation of the neighboring mRNA 
TNS4, an emerging oncogene with ties to PI3k signaling 
through stabilization of c-MET [20, 21] (Figure 19E-19G). 
This regulatory perturbation was not observed in 
Trametinib samples. Collectively, the molecular profiling 
of PDX models of hM1 suggests a potential explanation 
for Disulfiram’s ability to reduce tumor volume — through 
reduction of PI3K signaling [22, 23], and potentially 
through modulation of the noncoding transcriptome. 
Reads were aligned to the human genome (hg19) 
using hisat (with non-standard options -p 8 —qc-filter) 
and GENCODE annotation (v19, filtered for lincRNAs, 
processed transcripts, and protein coding genes) [24, 25]. 
Bams were quantified using cuffquant and differential 
expression analysis was performed with cuff diff using 
non-standard options -p 10, and a contrast sheet defining 
comparisons between Trametinib-vehicle, and Disulfiram-
vehicle [26]. All analyses were performed using 
cummerbund and other packages from bioconductor [27, 
28].
Target determination and adoptive cell transfer
For antigen discovery, the Yee lab at MD Anderson 
expanded patient-derived tumor cells (hMIA-2d) to 
approximately 108 cells (10 x 10 cm confluent plates), then 
lysed them using Triton X-100. Cell lysates were incubated 
overnight at 4°C with gentle agitation with 1 ug HLA-A, 
B, C specific mAb W6/32 for every 10 mg protein. Protein 
A/G Ultralink resin beads were used to immunoprecipitate 
HLA molecules, which were then directly eluted along 
with tumor-associated peptides using 0.1N acetic acid 
in five consecutive 1 mL eluates. Purification of HLA 
was confirmed by Western Blot analysis and HLA-
positive elutes were pooled and analyzed by tandem 
mass spectrometry (MS/MS), as described below. For 
discovery phase MS/MS, eluted HLA-bound peptides 
were injected onto a high-sensitivity HPLC system 
(Dionex 3000 RSLC), separated by reversed-phase 
chromatography in 0.1% formic acid water-acetonitrile on 
1.8 micron C18 (Agilent Technologies) and analyzed on 
an Orbitrap Elite mass spectrometer (Thermo Scientific) 
using data-dependent acquisition. The Mascot algorithm 
was employed to search acquired MS/MS spectra 
Figure 21: The number of DNA sequence reads of T-cell receptors from the T-cell product of the peptide amplification 
of the total leukapharesis (sample 1) and from the leukapheresis (sample 2). The high clonal counts of T-cell receptor sequences 
from the T-cell product of peptide expansion (in blue) and the leukapharesis (in orange) are presented and the sequences that are high clonal 
DNA sequence reads in both samples are in the upper right-hand corner.
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against the SwissProt complete human protein database 
using 10 ppm parent mass tolerance, 0.8 d fragment ion 
tolerance, Met oxidation, no enzyme selectivity. Search 
results were cross-referenced with the appropriate MHC-
binding specificities using the NetMHC 3.4 algorithm. 
Approximately 1800 peptides were detected in Discovery 
phase MS/MS, all corresponding to wild-type sequences 
matching proteins within the human proteome.
Based on the results of Discovery MS/MS, 
whole exome sequencing, and bioinformatics analysis 
considering target gene expression in normal tissues 
(GTex RNAseq databases), human pancreatic tumors 
(TCGA RNAseq database), and the patient’s own RNAseq 
analysis, 11 isotope- labeled high-confidence peptides of 
interest (8 mutated and 3 non-mutated) were synthesized 
and used as standards in a more sensitive targeted MS/
MS analysis. In this analysis, retention-time windows 
for the synthetic peptide standards of interest were pre-
determined by MS analysis of the synthetic peptides, then 
targeted methods for searching tumor-associated peptides 
were constructed using mass windows of 3 Da around 
each m/z. The targeted MS/MS experiments verified the 
presence of all 3 non-mutated peptides, but convincing 
MS evidence was not found for any of the predicted 
mutated peptides.
Generation of pancreatic antigen-specific CTL for 
adoptive therapy
Following identification of the 3 epitopes 
corresponding to pancreatic cancer-associated antigens 
(PCAA), clinical grade peptide and peptide-MHC 
tetramers were synthesized and used to generate PCAA-
specific CTL. All clinical investigations were conducted 
according to the Declaration of Helsinki principles.
The patient was enrolled on an approved protocol. The 
generation of antigen-specific CTL was performed 
according to methods established in the Yee Lab [29, 30]. 
Figure 22: The number of DNA sequence reads of T-cell receptors from the T-cell product of the peptide amplification 
(sample 1) and from the metastatic lung tumor (sample 2, TP_2047(y)). The high clonal counts of T-cell receptor DNA 
sequence reads from the T-cell product (in blue) and the metastatic lung tumor (in orange) are presented and the two blue sequence clones 
in the upper right corner of the graph are in common and in high amounts in both the amplified T-cell clones (Oct, 2015) and the tumor 
(Nov, 2013).
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Leukapheresis was performed to collect PBMCs, which 
were used as a source of stimulator (dendritic) cells and 
responder T cells. PBMCs were depleted of CD25+ T 
cells (Miltenyi Biotec Inc.) to eliminate regulatory T 
cells, and stimulated twice for seven days with autologous 
DC pulsed with PCAA peptide. DC stimulations were 
supplemented with IL-21 (30 ng/mL) on Day 1 and 
restimulated on Day 8 with IL-2 (10 U/ml) and IL-7 (10 
ng/ml). Cultures that contained ≥ 5% tetramer+ CD8+ 
T cells were sorted using a clinical grade cell sorter 
(Miltenyi Nanosorter) and expanded twice using the Rapid 
Expansion Protocol [31]. The total production time was 
6 weeks. Antigen-specificity was evaluated by testing 
against peptide-pulsed and antigen+ tumor targets. CTL 
were successfully expanded for one of the three peptides 
epitopes identified by targeted MS/MS. The purity and 
phenotype of the CTL product was defined immediately 
prior to infusion.
The PCAA-specific CTL line generated from patient 
peripheral blood specifically lysed PCAA-peptide pulsed 
targets; furthermore, robust and specific CTL killing of 
patient autologous tumor as well as an HLA-matched 
Table 1: 23 top hits that show >80% inhibition and 5 additional compounds of interest
hM1-CAF hM1-2D
Drug Name Final EC50 (M)
Averaged Max 
% Response








Dasatinib 58.9E-9 80 0.58 9.4E-9 83.75 0.35
Mithramycin 157.6E-9 93 2.56 174.1E-9 89.32 0.56
Teniposide 74.7E-9 94 0.50 482.6E-9 89.59 1.74
Methylrosanilinium 499.3E-9 101 0.06 489.1E-9 93.04 0.98
Gemcitabine 1.7E-9 96 9.21E-3 760.6E-12 93.78 0.29
Dactinomycin 3.8E-9 99 0.67 1.7E-9 94.30 0.29
Aclarubicin 610.8E-9 96 0.30 475.1E-9 94.77 0.76
Emetine 182.3E-9 100 0.18 118.3E-9 94.99 0.33
Epirubicin 84.5E-9 97 0.51 179.1E-9 95.41 0.84
Daunorubicin 38.8E-9 98 0.31 100.4E-9 95.59 0.60
Homoharringtonine 17.1E-9 99 0.20 14.1E-9 96.16 0.31
Topotecan 32.6E-9 97 0.08 312.8E-9 96.72 0.81
Idarubicin 10.7E-9 97 0.34 72.2E-9 96.85 0.51
Doxorubicin 90.6E-9 100 0.15 181.6E-9 96.89 1.07
Disulfiram 184.8E-9 59 12.08 316.6E-9 97.93 1.01
Dipyrithione 
magnesium sulfate 459.6E-9 93 6.61 428.8E-9 98.97 0.18
Bortezomib 1.4E-9 99 0.13 2.3E-9 99.25 0.14
Carfilzomib 2.6E-9 101 0.13 4.E-9 99.39 0.06
Romidepsin 952.8E-12 100 0.11 701.E-12 99.55 0.10
Auranofin 684.E-9 99 0.21 400.9E-9 99.55 0.07
Phanquinone 310.3E-9 99 1.14 105.8E-9 99.68 0.22
Thiram 596.4E-9 82 7.34 386.8E-9 100.10 0.07
Tyrothricin 407.2E-9 101 9.98E-3 491.5E-9 100.92 0.09
Afatinib 2.8E-6 94 3.05 226.3E-9 78.23 2.26
Neratinib 5.E-6 34 6.04 516.3E-9 67.78 1.49
Trametinib 5.E-6 38 5.35 2.7E-9 70.89 0.65
Oxaliplatin 5.E-6 11 2.82 5.E-6 10.49 2.86
Fluorouracil 5.E-6 33 9.34 5.E-6 45.58 2.18
Oncotarget14787www.oncotarget.com
PCAA+ tumor line was observed, suggesting that the 
Yee lab had isolated a CTL line of relatively high affinity, 
that the tumor expressed pMHC for the PCAA epitope of 
sufficient density, and that such a line may exhibit tumor 
rejection potential following adoptive transfer. The peptide 
target that generated T-cells against for the patient was an 
HLA-A*0101-restricted peptide derived from a protein 
product of the gene VGLL1 (gene name = “Vestigial-like 
1”).
Clinical protocol and course:
Under the protocol, the patient received CY (300mg/
m2 iv) on Day -2 and then an infusion of 1010 polyclonal, 
IL-21 primed antigen-specific CTL/m2, immediately 
followed by low-dose s.c. IL-2 and PD1 blockade (3mg/kg 
every 2 weeks x 16 doses) [32]. Radiologic responses were 
evaluated according to the mWHO-based irRC Criteria 
[33]. The patient received an infusion of T cells (1010 cells 
/m2: total 19 billion PCAA, pancreatic cancer associated 
antigen-specific CTL) 30 days apart, each followed by 
low-dose subcutaneous (s.c.) IL-2 (250,000 U/m2 every 
12h) and anti-PD1 every 3 weeks. The T-cell infusion 
was preceded by low-dose cyclophosphamide (CY) 
conditioning (300 mg/m2 x 1) and followed by a two-week 
course of low-dose subcutaneous IL-2. Although the entire 
regimen could be administered in the ambulatory setting, 
he was hospitalized for monitoring of potential cell-
infusion-associated adverse events (AEs). No serious AEs 
were observed apart from expected transient (<24 hours) 
culture-negative fevers (≥38.3ºC), associated with CTL-
induced cytokine release syndrome, and lymphopenia 
lasting 10 days [34].
Persistence, clonality, phenotype, and function of 
monoclonal and polyclonal CTL in vivo
Transferred T cells were tracked by TCR sequence 
analysis. High-throughput T cell receptor V beta 
sequencing (HTTCS) was used to identify individual 
clonotypes within CTL products, and track them in vivo 
post-infusion in both peripheral blood, pleural effusion, 
and lung biopsy samples. T cell receptor V beta analysis of 
the T cell product, which was > 95% tetramer positive for 
the target antigen, revealed that 99% of the TCR sequences 
were restricted to 21 clonotypes, the dominant clone, 
representing 43% of all sequences. HTTCS tracking of 
peripheral blood samples revealed a cumulative frequency 
(representing all 21 clonotypes) of 1.7% of total T cells in 
the PBMC with the dominant clonotype comprising more 
than 1% of total T cells. One month later, the transferred 
antigen-specific T cells were present at very low but 
detectable levels (.03%) in the periphery; however they 
had accumulated in the pleural effusion biopsy (0.37%). 
No infiltration into the lung tumor tissue was detected.
Overall, these results suggest that a relevant 
tumor-associated antigenic epitope could be identified 
from the patient tumor sample, and was of sufficient 
immunogenicity to elicit autologous pancreatic tumor-
reactive, antigen-specific T cells from patient peripheral 
blood. Isolation and expansion of such T cells for adoptive 
transfer was feasible, and the transferred T cells achieved 
relatively high frequency in the peripheral blood, with 
apparent enrichment in the pleural effusion, where they 
were detected at high frequency more than a month 
later. The lack of a significant clinical response may be 
attributable to a failure of T cells to infiltrate into the lung 
tissue and, notably, the loss of significant levels of the 
target antigen following adoptive transfer. Combination 
strategies to facilitate tumor infiltration and multivalent 
targeting (including antigen-spreading and targeting 
multiple antigens) may enhance clinical efficacy in future 
studies.
The T-cell receptor DNA sequence representations 
of cells from the tumor, the leukapheresis, and the 
selected amplification of T-cells
Samples of the pancreatic adenocarcinoma were 
taken from the metastatic tumor in the left lung extracted 
by thorascopic wedge resection in November 2013 for 
DNA sequencing of the genome, DNA sequencing of 
the T-cell receptor variable regions of the beta chain of 
the receptor (Figure 20, sample 2, blue points are each 
a different expanded clone sequence from the tumor) the 
production of organoids in cell culture, and patient derived 
murine xenografts. In Oct. 2015, T-cells from the patient 
were obtained by leukapharesis and a sample was obtained 
to sequence the variable regions of the beta chain of the 
T-cell receptor (Figure 20, orange points). The points 
(blue and orange) in the upper right-hand corner are clonal 
sequence counts (100 to 1,000 reads) in common with the 
tumor and the leukapharesis.
Some T-cell receptor sequences are common to all 
individuals with the same HLA class 1 types (so-called 
public sequences) so these clones, with high numbers of 
DNA sequence reads in both samples 1 and 2 of Figure 
20, do not necessarily mean detection of the same tumor 
antigen by an expanded DNA sequence clone in both the 
tumor and the blood. In October 2015, the leukapharesis 
sample (sample 2 of Figure 21) and the T-cell products 
that were expanded by a peptide (sample 1, Figure 21) 
were sequenced for the beta chain T-cell receptor variable 
region and compared. The clones in the upper right corner 
of the graph are found in both samples. It is notable that 
four blue clones (from the sample 1, T-cell product) are 
present in 10,000 copies, two of which are found in 10-
100 copies in the leukapharesis sample 2 counts and two 
in 1,000-10,000 copies in sample 2 leukaphares sample. 
Figure 22 provides the direct comparison of T-cell clone 
sequences shared by the T-cell peptide expanded clones 
and the clones found in the original tumor two years 
previously (Figure 22, blue clones). Two blue clones 
with 10,000 sequence reads in the T-cell product have 
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100-1,000 reads in the tumor. This does suggest that the 
T-cell preparation that was infused into the patient in 2015 
did contain a few clones with receptor sequences shared 
between the tumor and the expanded T-cell component and 
possibly targeting neoantigens in the tumor.
After the infusion of T-cells into the patient, 
(October 20, 2015) the patient continued to have tumor 
growth in the lung, as evidenced by increased tumor DNA 
markers in the blood, increased size of the lung lesions 
by imaging, and continued respiratory failures, although 
each of these observations could have been due to either 
an increased tumor load or a strong inflammation, killing 
cells in the tumor. A biopsy of the lung tumor at this 
time showed tissue sections with a small cell lung cancer 
phenotype. DNA sequencing of that biopsy material 
indicated that the tumor was derived from the original 
adenocarcinoma of the pancreas (both the RAS mutation 
and the p53 mutation at codon 175 were identical in both 
the pancreatic carcinoma and the small cell like lung 
cancer, as were other mutations found in the original tumor 
in 2013).The autopsy materials obtained in January 2016 
showed that tissue sections taken from many different 
parts of the lung tumor had a small cell lung cancer 
morphology (neuroendocrine-like), whereas other sections 
taken from different parts of the tumor had a pancreatic 
adenocarcinoma-like morphology, and some samples had 
mixed morphologies, with both cell types. The simplest 
interpretation of these observations is that a portion of 
the tumor underwent an epithelial-mesenchyme transition 
(EMT) giving rise to the small cell neuroendocrine-like 
morphology. This epigenetic change altered the pattern 
of gene expression and likely altered the neoantigens 
expressed by the original pancreatic adenocarcinoma 
tumor, giving rise to a failure of the T-cell therapy that was 
attempted. The observation that the increased levels of the 
Ras DNA biomarker sequence taken from the blood prior 
to the October 2015 infusion of T-cells into the patient, 
suggested that the EMT in the lung tumor began prior to 
any immune-selection of the adenocarcinoma tumor cells 
in the lung.
Whether the immune-selection actually worked to 
kill the pancreatic adenocarcinoma cells, and possibly 
to expand the neuroendocrine-like cells is unclear. 
What is clear was that there was a prolonged (several 
years) period of chemotherapy keeping the tumor 
metastasis under control, and biopsies demonstrate that 
this gives rise to increasing clonal heterogeneity of the 
tumor, perhaps resulting in an EMT with epigenetic 
changes and altered gene expression. Both genetic and 
morphological heterogeneity of the lung tumor is clear 
from the autopsy materials. This would be expected 
to alter the immunological profile of possible tumor 
antigens. Clearly, the tumor in vivo evolves under 
therapeutic selections and there is a need for greater 
monitoring and speed in understanding this evolution, 
so that the therapeutic choices keep up with the tumor 
evolution and heterogeneity. This applies to both the use 
of immunological therapies and chemical therapies, which 
were tested in organoids and mice carrying this tumor. In 
the future, we will need accurate and rapid laboratory 
processing of biopsy materials so as to respond to the 
information collected from the tumor in real time.
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